Literature DB >> 2416427

Synergistic antiproliferative effects of human recombinant alpha 54- or beta ser-interferon with gamma-interferon on human cell lines of various histogenesis.

J H Schiller, D S Groveman, S M Schmid, J K Willson, K B Cummings, E C Borden.   

Abstract

The antiproliferative effects of human interferon (IFN), IFN-gamma, IFN-alpha 54, and IFN-beta ser, alone and in combination, were assessed on 10 human cell lines. All IFNs were produced by recombinant technology and purified to homogeneity. In all cell lines except one, the addition of IFN-gamma to either IFN-alpha 54 or IFN-beta ser resulted in a synergistic antiproliferative effect, regardless of individual IFN sensitivities or tissue of origin. The only exception was a normal diploid fibroblast cell in which an additive antiproliferative effect occurred with combination IFN treatment. A malignant fibrosarcoma cell line of similar mesenchymal origin demonstrated a synergistic antiproliferative effect. One cell line was sensitive to both type I and type II IFN alone. Three cell lines were relatively resistant to IFN-gamma but not to IFN-beta ser, one was relatively resistant to IFN-beta ser but not to IFN-gamma, and the remainder were resistant to both IFN-gamma and IFN-beta ser or IFN-alpha 54. The addition of IFN-alpha 54 to IFN-beta ser in the SKCO 1 cell line resulted in an antagonistic interaction. Timing experiments with RT112 cells indicate that IFN-gamma and IFN-beta ser need not be in the media at the same time for the synergistic effect to occur. Combinations of type I and type II IFN thus resulted in synergistic antiproliferative effect for transformed human cells of various histogenesis, including some with a relative resistance to one or both IFN types.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416427

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A,B,C and DR in human urothelial cell lines.

Authors:  S S Ottesen; V Ahrenkiel; J Kieler
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 2.  Interferon in 1987: the half full glass.

Authors:  S E Krown
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Posttranscriptional regulation of c-myc proto-oncogene expression and growth inhibition by recombinant human interferon-beta ser17 in a human colon carcinoma cell line.

Authors:  D Chatterjee; T M Savarese
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic breast cancer.

Authors:  L Barreras; C L Vogel; G Koch; S G Marcus
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

5.  Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons.

Authors:  G M Graham; L Guarini; T A Moulton; S Datta; S Ferrone; P Giacomini; R S Kerbel; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Treatment of Ph+ chronic myeloid leukemia by gamma interferon.

Authors:  D Russo; R Fanin; E Zuffa; C Gallizia; M Grazia Michieli; D Damiani; N Testoni; V Pecile; G Visani; R Colombini
Journal:  Blut       Date:  1989-07

7.  The use of natural interferon alpha conjugated to a monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts.

Authors:  L Ozzello; C M De Rosa; E W Blank; K Cantell; R L Ceriani; D V Habif
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

Authors:  H O Klein; G Golbach; P Voigt; C Coerper; C Bernhardt
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Sensitivity of Ph 1 + CFU-GM to human recombinant interferon alpha and gamma alone and in combination.

Authors:  G Visani; D Russo; D Damiani; S Rizzi; M R Motta; R M Lemoli; C Poluzzi; R Fanin; E Zuffa; P Tosi
Journal:  Blut       Date:  1988-07

10.  Effects of scheduling and ascites-associated macrophages on combined antiproliferative activity of alpha-2b interferon and gamma-interferon in a clonogenic assay.

Authors:  J Higashihara; T Saito; M E Berens; C E Welander
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.